NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Regarding Doc's theory:

If NWBO is using the 4 subtype classification:

I do not know if just certain subtypes in the trial can be halted for efficacy. I'll probably let Doc site that rule instead of researching it.

However, if the DMC can do this, I think the halt for efficacy would be for 2 subtypes -- classic and mesenchymal. This is explained under several previous posts. Keywords "mesenchymal" and/or "classic."

That does not likely get you to the 80% response rate, so, under this hypothetical, the pro-neural and neural subtypes would likely continue in the trial.

To me, this peeling away of benefitted subtypes would be another 'systematic' chipping away from the barbaric (yet unavoidable -- so far) placebo trials. The cross-over arm is another way to do this. Interim analysis is another way to do this. They can cohesively play their parts in keeping people alive who might otherwise die in the old version of the double blinded placebo trials.